Literature DB >> 25173356

Urinary excretion of calcium, magnesium, phosphate, citrate, oxalate, and uric acid by healthy schoolchildren using a 12-h collection protocol.

Bernd Hoppe1.   

Abstract

Although we do not have reliable data for the true prevalence of urolithiasis during childhood, the number of patients seen in outpatient clinics and admitted for stone-related problems is steadily increasing worldwide. As for most pediatric patients a metabolic disease is the reason for stone development, because a high number of patients have severely recurrent urolithiasis, early and proper diagnostic evaluation is necessary to begin adequate and preventive treatment. However, diagnostic evaluation, especially in infants and younger children, is not always easy, and frequently a diagnosis is made late. Diagnostic evaluation should start with repeated urine analysis; but how and which urine should be collected and analyzed? What is the best and most accurate method for urine collection? In a paper published in a recent issue of Pediatric Nephrology, Torres and colleagues describe a more simplified method of urine collection. They propose analysis of late-afternoon spot-urine samples as well as an overnight collection of urine as the most appropriate to evaluate patient-specific urinary risk factors. Is this truly the case?

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25173356     DOI: 10.1007/s00467-014-2925-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

1.  Nephrocalcinosis and urolithiasis in children.

Authors:  Sandra Habbig; Bodo Bernhard Beck; Bernd Hoppe
Journal:  Kidney Int       Date:  2011-09-28       Impact factor: 10.612

2.  Twenty-four hour and spot urine metabolic evaluations: correlations versus agreements.

Authors:  Yet Hoi Hong; Norman Dublin; Azad Hassan Razack; Mustafa Ali Mohd; Ruby Husain
Journal:  Urology       Date:  2009-11-14       Impact factor: 2.649

Review 3.  A vertical (pseudodominant) pattern of inheritance in the autosomal recessive disease primary hyperoxaluria type 1: lack of relationship between genotype, enzymic phenotype, and disease severity.

Authors:  B Hoppe; C J Danpure; G Rumsby; P Fryer; P R Jennings; N Blau; G Schubiger; T Neuhaus; E Leumann
Journal:  Am J Kidney Dis       Date:  1997-01       Impact factor: 8.860

Review 4.  Aetiological factors in paediatric urolithiasis.

Authors:  William G van't Hoff
Journal:  Nephron Clin Pract       Date:  2004

5.  Oxalate, citrate, and sulfate concentration in human milk compared with formula preparations: influence on urinary anion excretion.

Authors:  B Hoppe; B Roth; C Bauerfeld; C B Langman
Journal:  J Pediatr Gastroenterol Nutr       Date:  1998-10       Impact factor: 2.839

6.  Urinary excretion of calcium, magnesium, phosphate, citrate, oxalate, and uric acid by healthy schoolchildren using a 12-h collection protocol.

Authors:  Concepción Sáez-Torres; Dolores Rodrigo; Félix Grases; Ana M García-Raja; Cristina Gómez; Javier Lumbreras; Guiem Frontera
Journal:  Pediatr Nephrol       Date:  2014-02-12       Impact factor: 3.714

Review 7.  Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria.

Authors:  Bernd Hoppe; Ernst Leumann; Gerd von Unruh; Norbert Laube; Albrecht Hesse
Journal:  Front Biosci       Date:  2003-09-01

8.  Assessment of crystallization risk formulas in pediatric calcium stone-formers.

Authors:  Przemysław Sikora; Małgorzata Zajaczkowska; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2009-03-31       Impact factor: 3.714

9.  Random urinary calcium/creatinine ratio for screening hypercalciuria in children with hematuria.

Authors:  In Su Choi; Eui Seok Jung; Young Earl Choi; Young Kuk Cho; Eun Mi Yang; Chan Jong Kim
Journal:  Ann Lab Med       Date:  2013-10-17       Impact factor: 3.464

Review 10.  Diagnostic examination of the child with urolithiasis or nephrocalcinosis.

Authors:  Bernd Hoppe; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2008-12-23       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.